astrazeneca

Recent 52-Week High Exceeded in Shares of AstraZeneca (AZN)

Published on Wed, 12/12/2012 - 15:07
By Adrienne Chilton in 52 Week high-lows, AZN, 52 week high/lows, astrazeneca, nyse:azn
AZN

By Adrienne Chilton
achilton@fnno.com

Volume Spike Detected in Shares of AstraZeneca as They Move Higher on 1.6x Above-Average Volume (AZN)

Published on Wed, 12/12/2012 - 14:11
By Peter Chu in Unusual volume, AZN, astrazeneca, nyse:azn, unusual volume
AZN

By Peter Chu
pchu@fnno.com

Buyers Accumulate Shares of AstraZeneca, Up 2.2%

Published on Fri, 11/23/2012 - 13:20
By Mallory Stone in Market movers, AZN, astrazeneca, market movers, nyse:azn
AZN

By Mallory Stone
mstone@fnno.com

AstraZeneca To Buy Ardea Biosciences for $1.26 Billion

Published on Mon, 04/23/2012 - 10:19
By FNNO Staff in acquisition, analysis, ardea biosciences, astrazeneca, azn, business, finance, investing, market, merger, news, stock, trading
azn, astrazeneca, merger, acquisition, ardea biosciences, business, finance, investing, stock, news, trading, analysis, market

By FNNO Staff
fnnonline@gmail.com

Delaware Court Rules Mylan Generic Doesn't Infringe Upon AstraZeneca Patent

Published on Fri, 06/24/2011 - 08:02
By FNNO Staff in General Interest, astrazeneca, azn, business, finance, investing, market, myl, mylan, news, share, stock, News Update

Mylan received final approval form the FDA for the Budesonide capsules on May 16, 2011. It is the generic version of AstraZeneca's Entocort EC capsules. It is the first generic version of the drug to be introduced in the U.S.

Budesonide had sales in the U.S.

astrazeneca, azn, business, finance, investing, market, myl, mylan, news, share, stock

Mylan Inc. (NASDAQ:MYL) announced today that the U.S. District Court for Delaware has found that the company's Budesonide Capsules do not infringe upon AstraZeneca's (NYSE:AZN) patent for its Entocort EC capsules, a treatment for

By FNNO Staff
fnnonline@gmail.com

Morning Market Snapshot: April 7, 2011

Published on Thu, 04/07/2011 - 07:35
By FNNO Staff in General Interest, 3m, analysis, astrazeneca, azn, business, financial, hot, market, mmm, news, starwood, stock, trading, Market Snapshot
3m, analysis, astrazeneca, azn, business, financial, hot, market, mmm, news, starwood, stock, trading

3M (MMM) is set to expand manufacturing in China for solar markets. AstraZeneca (AZN) announces FDA approval of Vandetanib. Merck (MRK) announced that the FDA declined to widen Gardasil to women older than 26. Starwood H

By FNNO Staff
fnnonline@gmail.com

Healthcare Sector Update: March 17, 2011

analysis, astrazeneca, business, ethyphram, financial, healthcare, johnson & johnson, market, merck, news, sector, stock, teva pharmaceuticals, trading

Health care shares are higher in mid-day trading while Merck (MRK) and Johnson & Johnson (JNJ) get a key approval in the UK. In mid-day news, AstraZeneca (AZN) is defending its best-selling heartburn and stomach ulcer medicati

By FNNO Staff
fnnonline@gmail.com

AstraZeneca Settles Seroquel Marketing Suit for $68.5M

Published on Thu, 03/10/2011 - 16:23
By FNNO Staff in General Interest, analysis, astrazeneca, azn, business, financial, lawsuit, market, news, seroquel, stock, trading, News Update

The settlement is the largest multi-state, consumer protection pharmaceutical settlement of record, reports Reuters.

Regulators accused the company of unfair and misleading marketing of the drug for unapproved uses. While physicians can prescribe medication for other uses, companies are not allowed to market drugs beyond approved uses.

analysis, astrazeneca, azn, business, financial, lawsuit, market, news, seroquel, stock, trading

AstraZeneca (NYSE:AZN) will pay $68.5 million to 37 states and the District of Columbia in a settlement over the British drugmaker's deceptive marketing of its anti-psychotic drug Seroquel.

By FNNO Staff
fnnonline@gmail.com

UBS Downgrades AstraZeneca To Neutral (AZN)

Published on Wed, 03/02/2011 - 12:21
By Stephanie Shyu in General Interest, AZN, analysis, astrazeneca, business, finance, market, share, stock, ubs, Analyst Actions
analysis, astrazeneca, business, finance, market, share, stock, ubs

UBS downgraded AstraZeneca (NYSE:AZN) to neutral from buy, on a shift in sector preferences. AstraZeneca is trading down 0.2% to $48.32 per share.

By Stephanie Shyu
sshyu@fnno.com

Healthcare Sector Update: February 17, 2011

adr, analysis, astrazeneca, business, financial, graham cooper, healthcare, market, news, orexigen therapeutics, sector, stock, trading, update

Health care shares are lower in mid-session trading while AstraZeneca (AZN) continues to take steps to settle lawsuits over its Seroquel drug. ADRs of AstraZeneca are down on a Bloomberg report the drug maker paid $150 million to

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

Recent 52-Week High Exceeded in Shares o...

Shares of Zimmer (NYSE:ZMH) traded today at $81.72, breaking its 52-week high. This ne ...

Watch for Continued Gains in Shares of Y...

Shares of Yingli Green Energy (NYSE:YGE) traded at a new 52-week high today of $4.83. ...

Shares of Crosstex Energy Have Risen Abo...

Shares of Crosstex Energy (NASDAQ:XTEX) traded today at $21.15, breaking its 52-week hi ...

Recent 52-Week High Exceeded in Shares o...

Shares of Washington Real Estate Investment Trust (NYSE:WRE) traded at a new 52-week hi ...

Shares of Weatherford International Have...

Weatherford International (NYSE:WFT) traded today at a new 52-week high of $14.46. Thi ...

Waste Connections: 52-Week High Recently...

Waste Connections (NYSE:WCN) traded today at a new 52-week high of $40.70. So far toda ...

Shares of USANA Health Sciences Rise Abo...

Shares of USANA Health Sciences (NYSE:USNA) traded at a new 52-week high today of $68.9 ...

Shares of Umpqua Holdings Rise Above Pre...

Umpqua Holdings (NASDAQ:UMPQ) traded today at a new 52-week high of $13.91. Approximat ...

Most Popular Video News